Navigation Links
Regulus Therapeutics Forms Strategic Alliance for Discovery, Development and Commercialization of microRNA Therapeutics with AstraZeneca
Date:8/14/2012

s, cancer and potentially other therapeutic areas of interest to AstraZeneca."

"Regulus is pleased to form another significant strategic alliance on microRNA therapeutics," said Kleanthis G. Xanthopoulos, Ph.D., President and Chief Executive Officer of Regulus Therapeutics Inc. "AstraZeneca is a global, innovation-driven company that we believe can greatly aid our efforts to advance microRNA therapeutics to the clinic and the market. The entire field of RNA therapeutics has been rapidly advancing, reaching significant milestones recently. We are committed to realize the broad utility of these new RNA-based medicines to treat human disease in the future. "

Neil W. Gibson, Ph.D., Chief Scientific Officer of Regulus Therapeutics Inc., added, "We wanted to partner our microRNA-33 program with AstraZeneca due to their excellent track record on developing and commercializing drugs in cardiovascular and metabolic diseases and their commitment to the RNA therapeutic field.  We look forward to growing our strategic relationship with AstraZeneca with additional targets to develop important first-in-class medicines."

About microRNA-33 for Atherosclerosis

Atherosclerosis is the build-up of plaque that occurs when cholesterol and inflammatory cells accumulate in blood vessels. These plaques can rupture, leading to slowing or blockage of blood flow and ultimately resulting in a heart attack or stroke. Scientific research has shown a strong correlation between high cholesterol levels and cardiovascular disease which, according to the Centers for Disease Control, is the leading cause of death in the United States.

Regulus' lead program for atherosclerosis targets microRNA-33, which has a unique mechanism of action for the management of cholesterol levels. The inhibition of microRNA-33 with our anti-miRs promotes reverse cholesterol transport, or RCT, which is the efflux of cholesterol from specific cholesterol-laden inflammatory cells calle
'/>"/>

SOURCE Regulus Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Nile Therapeutics Reports 2012 Second Quarter Financial Results
2. Zenobia Therapeutics Announce A Partnership With The Alzheimers Drug Discovery Foundation
3. Elcelyx Therapeutics Names Mark Wiggins Senior Vice President of Business Development, Ginger Graham to Board of Directors
4. Echo Therapeutics Announces Second Quarter 2012 Financial Results
5. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
6. Echo Therapeutics Announces $20 Million Financing with Platinum-Montaur Life Sciences
7. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
8. Cempra, Inc. to Present at the NIAID Workshop Bridging the Gap - Overcoming Bottlenecks in the Development of Therapeutics for Infectious Diseases
9. Nile Therapeutics Promotes Darlene Horton, M.D., to Chief Executive Officer and Director
10. Retinal Vein Occlusion Therapeutics - Pipeline Assessment and Market Forecasts to 2019
11. Silence Therapeutics - Admission of Shares and Board Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , July 31, 2015  Physicians and payers ... the biopharmaceutical market. Patients are better informed and ... and switching therapies. This shift in power is ... efforts toward patient-focused marketing. As part ... have learned it,s important to educate, communicate and ...
(Date:7/31/2015)... N.C. , July 31, 2015  In today,s ... customers who are increasingly mobile, increasingly connected, and increasingly ... growing variety of customer interaction channels and tools is ... including social media. According to research ... over the counter (OTC) segment in a call center ...
(Date:7/31/2015)... -- Seeger Weiss LLP is reporting that on July 13, 2015, ... C.R. Bard, the manufacturer of Inferior vena cava (IVC) ... the agency found at two of Bard,s facilities. Bard was ... them during Inspectional Observations that occurred on November 18, 2014, ... , location and on October 6, 2014, through November ...
Breaking Medicine Technology:Consumers Forcing Pharmaceutical Industry to Shift its Marketing Focus from Products to Patients 2Best Practices in Building World-Class Consumer & Over-the-Counter Call Centers 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 3
... , Accreditation Organization to ... , WASHINGTON , Feb. 17 ... will conduct a workshop on "Medication Adherence and Medication Possession Ratio ... Management Institute (PBMI) Conference in Phoenix, Ariz. The ...
... CORDOVA, Calif. , Feb. 17 AMPAC Fine ... APFC ), announced today that it has entered into ... (Inabata).  The purpose of the collaboration is to provide ... that AFC has developed for successfully manufacturing active pharmaceutical ingredients ...
Cached Medicine Technology:URAC Showcases Performance Measures for Pharmacy Benefit and Drug Therapy Management Programs 2URAC Showcases Performance Measures for Pharmacy Benefit and Drug Therapy Management Programs 3URAC Showcases Performance Measures for Pharmacy Benefit and Drug Therapy Management Programs 4AMPAC Fine Chemicals Partners With Inabata & Co., Ltd. of Japan 2AMPAC Fine Chemicals Partners With Inabata & Co., Ltd. of Japan 3AMPAC Fine Chemicals Partners With Inabata & Co., Ltd. of Japan 4
(Date:8/1/2015)... ... August 01, 2015 , ... Calvary Hospital today announced that ... their Bronx campus. The goal is to bring this Torah – dating from 1880 ... Jewish rituals and religious services. , Scroll No. 515, from the town of ...
(Date:8/1/2015)... (PRWEB) , ... August 01, 2015 , ... Tina Wilcoxson, ... Champions.” , Wilcoxson was given that honor by the National Retail Federation, the largest ... industry. Wilcoxson was one of three Maine business owners to be named as such. ...
(Date:8/1/2015)... ... August 01, 2015 , ... Brig and Lita Hart, ... announcing the unification of their Healthy Home mission with the HOPE Movement of EvolvHealth. ... the founders of both companies have agreed to join their missions of purpose together ...
(Date:8/1/2015)... CT (PRWEB) , ... August 01, 2015 , ... ... Point Partners I, L.P. (“GPP”) portfolio company has acquired Premier Physical Therapy & ... it into its portfolio of state-of-the-art clinics. , “Our acquisition of Premier Physical ...
(Date:8/1/2015)... ... August 01, 2015 , ... On Tuesday, July 28th, Symantec released a security ... have been behind the attack on Anthem Inc. which resulted in one of the ... hole attacks and spear phishing campaigns. , For Joe Caruso, founder and ...
Breaking Medicine News(10 mins):Health News:Calvary Hospital Announces Plans to Restore Historic Torah 2Health News:Calvary Hospital Announces Plans to Restore Historic Torah 3Health News:Local Retail Advocate Wins National Recognition 2Health News:Looking for HOPE? Healthy Home Has Evolv’d 2Health News:Looking for HOPE? Healthy Home Has Evolv’d 3Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 2Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 4
... May 8 (HealthDay News) -- People at risk for celiac ... they show no symptoms, a new study suggests. Celiac ... small intestine when the person consumes gluten, a protein found ... with the disease has grown rapidly in recent decades, but, ...
... , MONDAY, May 9 (HealthDay News) -- Some ... emotional reactions to everyday situations, a combination that appears ... a Massachusetts General Hospital study that included 83 participants ... deficient emotional self-regulation (DESR), 33 with neither condition -- ...
... of U.S. children taken to hospital emergency departments (EDs) for ... ease worried parents, concerns. Yet true traumatic brain injury is ... minor blunt head trauma, led by Children,s Hospital Boston and ... reduce the use of head CT by as much as ...
... UK,s betting shops are attracting a new type of ... terms of problem gambling, argues initial research findings funded ... Betting shops today are virtually unrecognisable compared to the ... Act. "Under the Act, the newly licensed betting offices ...
... -- (May 9, 2011) In the wild, mammals survive ... shadowy bushes. That ability translates to the human ... in an image of our messy and stuffed suitcases. We ... our car keys on that cluttered shelf next to the ...
... patient without common symptoms of celiac disease is accurately ... study from the Beth Israel Deaconess Medical Center in ... divided the cases of nearly 800 adult patients with ... per capita earnings. Some patients had complained of acute ...
Cached Medicine News:Health News:More People May Benefit From Going Gluten-Free 2Health News:ADHD With Poor Emotional Control Seems to Run in Families 2Health News:Large study finds CT scans are frequently unnecessary after head injury in children 2Health News:Large study finds CT scans are frequently unnecessary after head injury in children 3Health News:50 years on, UK betting shops lure new breed of punters 2Health News:The brain performs visual search near optimally 2
Super High Density, multi-frequency, phased array burr hole transducer. Excellent for taking biopsy samples and shunt placements....
High resolution, multi-frequency, HST version of the UST-987-7.5. Provides even greater image detail, better resolution, and penetration....
... Super High Density, multi-frequency, ... new "twist on the UST-5536, ... flexes, it sweeps horizontally as ... central axis so that target ...
Super High Density, multi-frequency "I shaped convex intraoperative transducer. The UST-995-7.5 nestles comfortably between your index and middle fingers so that you can palpate organs while scanning...
Medicine Products: